BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 33109569)

  • 1. Development of an Oncolytic Recombinant Vesicular Stomatitis Virus Encoding a Tumor-suppressor MicroRNA.
    Sakuda T; Kubo T; Johan MP; Furuta T; Sakaguchi T; Adachi N
    Anticancer Res; 2020 Nov; 40(11):6319-6325. PubMed ID: 33109569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic Effect of a Recombinant Vesicular Stomatitis Virus Encoding a Tumor-suppressor MicroRNA in an Osteosarcoma Mouse Model.
    Sakuda T; Kubo T; Johan MP; Furuta T; Sakaguchi T; Adachi N
    Anticancer Res; 2023 Mar; 43(3):1185-1191. PubMed ID: 36854523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma.
    Shin EJ; Wanna GB; Choi B; Aguila D; Ebert O; Genden EM; Woo SL
    Laryngoscope; 2007 Feb; 117(2):210-4. PubMed ID: 17204993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
    Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.
    Seegers SL; Frasier C; Greene S; Nesmelova IV; Grdzelishvili VZ
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic vesicular stomatitis virus administered by isolated limb perfusion suppresses osteosarcoma growth.
    Kubo T; Shimose S; Matsuo T; Fujimori J; Sakaguchi T; Yamaki M; Shinozaki K; Woo SL; Ochi M
    J Orthop Res; 2011 May; 29(5):795-800. PubMed ID: 21437961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential infection of murine and human dendritic cell subsets by oncolytic vesicular stomatitis virus variants.
    Pipperger L; Riepler L; Kimpel J; Siller A; Stoitzner P; Bánki Z; von Laer D
    Oncoimmunology; 2021; 10(1):1959140. PubMed ID: 34484872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV.
    Velazquez-Salinas L; Naik S; Pauszek SJ; Peng KW; Russell SJ; Rodriguez LL
    Hum Gene Ther Clin Dev; 2017 Jun; 28(2):108-115. PubMed ID: 28514874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastatic tumor cells detection and anti-metastatic potential with vesicular stomatitis virus in immunocompetent murine model of osteosarcoma.
    Johan MP; Kubo T; Furuta T; Sakuda T; Sakaguchi T; Nakanishi M; Ochi M; Adachi N
    J Orthop Res; 2018 Sep; 36(9):2562-2569. PubMed ID: 29637599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.
    Naik S; Nace R; Barber GN; Russell SJ
    Cancer Gene Ther; 2012 Jul; 19(7):443-50. PubMed ID: 22522623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.
    Willmon C; Diaz RM; Wongthida P; Galivo F; Kottke T; Thompson J; Albelda S; Harrington K; Melcher A; Vile R
    Mol Ther; 2011 Jan; 19(1):140-9. PubMed ID: 20978474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer.
    Chang G; Xu S; Watanabe M; Jayakar HR; Whitt MA; Gingrich JR
    J Urol; 2010 Apr; 183(4):1611-8. PubMed ID: 20172545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Curcumin promotes the oncoltyic capacity of vesicular stomatitis virus for the treatment of prostate cancers.
    Fehl DJ; Ahmed M
    Virus Res; 2017 Jan; 228():14-23. PubMed ID: 27865863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
    Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
    J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
    Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
    Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer upregulated gene 2, a novel oncogene, confers resistance to oncolytic vesicular stomatitis virus through STAT1-OASL2 signaling.
    Malilas W; Koh SS; Srisuttee R; Boonying W; Cho IR; Jeong CS; Johnston RN; Chung YH
    Cancer Gene Ther; 2013 Feb; 20(2):125-32. PubMed ID: 23306614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the Impact of Oncolytic Vesicular Stomatitis Virus on the Trafficking, Phenotype, and Antigen Presentation Potential of Neutrophils and Their Ability to Acquire a Non-Structural Viral Protein.
    Stegelmeier AA; Chan L; Mehrani Y; Petrik JJ; Wootton SK; Bridle B; Karimi K
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32882969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy.
    Janelle V; Brassard F; Lapierre P; Lamarre A; Poliquin L
    J Virol; 2011 Jul; 85(13):6513-20. PubMed ID: 21561919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency.
    Muik A; Stubbert LJ; Jahedi RZ; Geiβ Y; Kimpel J; Dold C; Tober R; Volk A; Klein S; Dietrich U; Yadollahi B; Falls T; Miletic H; Stojdl D; Bell JC; von Laer D
    Cancer Res; 2014 Jul; 74(13):3567-78. PubMed ID: 24812275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy.
    Bishnoi S; Tiwari R; Gupta S; Byrareddy SN; Nayak D
    Viruses; 2018 Feb; 10(2):. PubMed ID: 29473868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.